NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets closed

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.23+0.01 (+0.02%)
At close: 4:00 PM EST
People also watch:
ALKSLGNDPGNXNKTRINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close43.22
Open43.14
Bid40.60 x 100
Ask54.97 x 1000
Day's Range42.47 - 44.22
52 Week Range31.25 - 57.82
Volume935,345
Avg. Volume897,493
Market Cap3.76B
Beta0.65
PE Ratio (TTM)-29.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist2 days ago

    Uterine Fibroids Segment May Offer Opportunity for NBIX

    According to MarketScan and Truven Health Analytics, approximately 9 million women in the US need therapy for symptoms related to uterine fibroids (or UF).

  • Capital Cube2 days ago

    ETFs with exposure to Neurocrine Biosciences, Inc. : December 2, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Neurocrine Biosciences, Inc. Here are 5 ETFs with the largest exposure to NBIX-US. Comparing the performance and risk of Neurocrine Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Market Realist2 days ago

    Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix

    While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).